Purple biotech announces receipt of nasdaq minimum bid price notification

Rehovot, israel, oct. 20, 2025 (globe newswire) -- purple biotech ltd. (“purple biotech” or “the company”) (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that on october 16, 2025, it received a letter from the listings qualifications department of the nasdaq stock market llc ("nasdaq") notifying the company that it is not in compliance with the minimum bid price requirement set forth in nasdaq listing rules for continued listing on the nasdaq capital market, as the closing bid price for the company's american depositary shares (adss) has been below the minimum $1.00 per share requirement under nasdaq listing rule 5550(a)(2) for 30 consecutive trading days.
PPBT Ratings Summary
PPBT Quant Ranking